Dose escalation effectiveness and tolerability of paroxetine in patients with burning mouth syndrome and depressive conditions. Issue 3 (May 2015)

• Record Type: Journal Article
• Authors: Ohga, Noritaka; Yamazaki, Yutaka; Sato, Jun; Hata, Hironobu; Murata, Tsubasa; Sakata, Kenichiro; Inoue, Takeshi; Kitagawa, Yoshimasa
• Is Part Of: Journal of oral and maxillofacial surgery, medicine, and pathology. Volume 27:Issue 3(2015)
• Page Start: 402
• Page End: 406
• Publication Date: 2015-05
• Subjects: Mouth -- Surgery -- Periodicals; Face -- Surgery -- Periodicals; Maxilla -- Surgery -- Periodicals; Oral medicine -- Periodicals; Mouth -- Diseases -- Pathogenesis -- Periodicals; Surgery, Oral -- Periodicals; Oral Medicine -- Periodicals; Pathology, Oral -- Periodicals; Face -- Surgery; Maxilla -- Surgery; Mouth -- Diseases -- Pathogenesis; Mouth -- Surgery; Oral medicine; Electronic journals -- Sciences; Electronic journals -- Medicine; Periodicals; 617.522059
• DOI: 10.1016/j.ajoms.2015.02.001
• Languages: English
• ISSNs: 2212-5566

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <title id="sect0010">Objective</title> <p id="spar0005">To evaluate gradual dose escalation and tolerability of paroxetine in patients with burning mouth syndrome (BMS).</p> </sec> <sec> <title id="sect0015">Methods</title> <p id="spar0010">This 12-week, open-label, non-comparative, prospective study involved 43 subjects with depressive condition. The initial dosage of paroxetine was 10 mg/day, but was raised to 20 mg/day and 30 mg/day if efficacy was not sufficient. Pain was assessed using the visual analog scale (VAS) at baseline and at weeks 2, 4, 8, and 12 of the study treatment.</p> </sec> <sec> <title id="sect0020">Results</title> <p id="spar0015">The mean VAS score at each time point was significantly lower than at baseline (<italic>P</italic> < 0.0001, paired <italic>t</italic>-test) after paroxetine treatment. The effects of paroxetine were dose-dependent. The cumulative improvement rates for daily doses of 10 mg, 20 mg, and 30 mg were 37.2%, 67.4%, and 74.4%, respectively. The cumulative proportion of responders was significantly higher for patients with maximal daily doses of 20 mg and 30 mg than in patients receiving 10 mg/day (<italic>P</italic> < 0.01, <italic>χ</italic><sup>2</sup> test). Adverse events were observed in 26 of 49 (53%) patients evaluated for safety, with most adverse events appearing when patients were taking 10 mg/day. The incidence of adverse events did not show a time- or dose-dependent increase, except for constipation. No serious safety issues were noted.</p> </sec> <sec> <title id="sect0025">Conclusions</title> <p id="spar0020">Dose escalation of paroxetine may be useful in treating patients with BMS and depressive conditions.</p> </sec> </abstract>